Are we over-treating with checkpoint inhibitors?
Published version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Anti-PD-1 antibodies offer potentially life-saving treatment for some cancer patients, but their chronic administration generates high and ever-increasing costs. Despite licensing for long-term use, optimal treatment duration is unknown. We challenge the need for long-term treatment duration, using evidence from melanoma research, both published and in process.
Description
Keywords
Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Duration of Therapy, Humans, Ipilimumab, Melanoma, Nivolumab, Programmed Cell Death 1 Receptor, Skin Neoplasms
Is Part Of
Publisher
Springer Science and Business Media LLC
